In April 2022, FDA granted Orphan Drug Designation (ODD) to TTI-101, an orally delivered, small molecule, STAT3 inhibitor developed by Tvardi Therapeutics, Inc., for HCC treatment.
👉🏻 𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭 𝐇𝐞𝐩𝐚𝐭𝐨𝐜𝐞𝐥𝐥𝐮𝐥𝐚𝐫 𝐂𝐚𝐫𝐜𝐢𝐧𝐨𝐦𝐚 (𝐇𝐂𝐂) 𝐌𝐚𝐫𝐤𝐞𝐭:- https://www.marknteladvisors.c....om/research-library/
#hepatocellular_carcinoma_market #hepatologist #cancerresearch #hepatitis #chemotherapy #biotechnology #pharmaceutical #carcinoma #marketresearch #marknteladvisors #healthcare
